Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received
Announces distribution of approximately 83,000 specimen collection kits to clients SAN DIEGO , Sept. 16, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
View HTML
Toggle Summary Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14
SAN DIEGO , Sept. 9, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces that President and CEO Michael Nall will present at the
View HTML
Toggle Summary Biocept Executes In-Network Provider Agreement with Health Net Federal Services Extending Coverage for its Liquid Biopsy Oncology Platform to the TRICARE West Region Network
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has entered into an agreement with Health Net Federal
View HTML
Toggle Summary Biocept Announces One-for-Ten Reverse Stock Split
SAN DIEGO , Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that, as a result of the Company's one-for-ten reverse stock
View HTML
Toggle Summary Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed
Announces distribution of approximately 46,000 specimen collection kits to clients SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
View HTML
Toggle Summary Biocept to Present at the LD Micro 500 Virtual Conference
SAN DIEGO , Aug. 27, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the
View HTML
Toggle Summary Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
SAN DIEGO , Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan , M.D.
View HTML
Toggle Summary Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
SAN DIEGO , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at
View HTML
Toggle Summary Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
SAN DIEGO , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with MultiPlan,
View HTML
Toggle Summary Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers
Expands Company's patent portfolio and marks another step in pursuit of worldwide intellectual property protection for proprietary Primer-Switch technology used to detect rare events such as cancer biomarkers found in tissue and liquid biopsies SAN DIEGO , Aug.
View HTML